Article
Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center.
Internal medicine (Tokyo, Japan) - 15 Jun 2023
Nakagawa Yosuke, Toyoda Masao, Saito Nobumichi, Kaneyama Noriko, Shimizu Tomomichi, Mabuchi Tomotaka, Fukagawa Masafumi
Abstract excerpt
Objective Several studies have shown an increased risk of bullous pemphigoid (BP) when receiving dipeptidyl pepitidase-4 inhibitor (DPP-4i) treatment. The present study explored the associations of DPP-4i treatment with the clinical phenotypes and clinical course of BP. Methods We analyzed data of 146 patients with BP at Tokai University School of Medicine from December 1, 2009, to December 31, 2021. We obtained...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.